Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CUE 
Cue Biopharma (CUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: CUE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.87% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.34M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 4 | Beta 1.55 | 52 Weeks Range 0.54 - 1.99 | Updated Date 10/25/2025 |
52 Weeks Range 0.54 - 1.99 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -292.32% |
Management Effectiveness
Return on Assets (TTM) -59.43% | Return on Equity (TTM) -195.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35363466 | Price to Sales(TTM) 7.28 |
Enterprise Value 35363466 | Price to Sales(TTM) 7.28 | ||
Enterprise Value to Revenue 4.27 | Enterprise Value to EBITDA -1.76 | Shares Outstanding 76845904 | Shares Floating 76580017 |
Shares Outstanding 76845904 | Shares Floating 76580017 | ||
Percent Insiders 0.35 | Percent Institutions 22.6 |
Upturn AI SWOT
Cue Biopharma
Company Overview
History and Background
Cue Biopharma, founded in 2011, is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics to selectively engage and modulate the human immune system directly within the body to treat cancer, autoimmune diseases, and infectious diseases.
Core Business Areas
- Immuno-Oncology: Developing CUE-100 series of biologics that are designed to engage and activate cancer-specific T cells within the patientu2019s body to promote an anti-tumor response.
- Autoimmune Diseases: Exploring opportunities to apply its Immuno-STATETM platform in the development of therapeutics for autoimmune disorders.
- Infectious Diseases: Researching the potential of Cue Biopharmau2019s technology to treat various infectious diseases.
Leadership and Structure
The leadership team includes Ayaclar, Kermit, M.D. (Chief Executive Officer), and Dr. Anish Suri (Chief Scientific Officer). The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- CUE-101: CUE-101 is Cue Biopharma's lead Immuno-STATETM clinical candidate for the treatment of recurrent/metastatic HPV16+ Head and Neck Squamous Cell Carcinoma (HNSCC). Currently in Phase 1b/2 clinical trials. Market share is not yet applicable as it's in clinical stage. Competitors include companies developing immunotherapy for head and neck cancer, such as Merck (Keytruda) and Bristol Myers Squibb (Opdivo).
- CUE-102: CUE-102 is designed to target the Wilms' Tumor 1 (WT1) antigen, which is overexpressed in multiple cancer types. Preclinical stage. Market share is not yet applicable. Competitors include companies developing WT1-targeted therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing significant growth, driven by advancements in immunotherapy and targeted therapies. There is a high demand for innovative solutions to address cancer and autoimmune diseases.
Positioning
Cue Biopharma is positioned as an innovative biotech company pioneering a novel approach to immunotherapy with its Immuno-STATETM platform. Its competitive advantage lies in its ability to directly engage and modulate T cells in vivo.
Total Addressable Market (TAM)
The total addressable market for immunotherapy is estimated to be in the tens of billions of dollars. Cue Biopharma is positioned to capture a portion of this market with its targeted immuno-oncology therapies.
Upturn SWOT Analysis
Strengths
- Novel Immuno-STATETM platform
- Targeted immuno-oncology approach
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Clinical development risks
- Reliance on external collaborations
- Not yet commercially launched product.
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the Immuno-STATETM platform to other disease areas
- Positive clinical trial results
- Advancements in personalized medicine
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- NVS
Competitive Landscape
Cue Biopharma competes with established pharmaceutical companies in the immunotherapy space. Its advantage lies in its novel Immuno-STATETM platform, but it faces challenges related to financial resources and clinical development.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by research and development progress and partnerships.
Future Projections: Future growth is dependent on clinical trial success and potential commercialization of its products. Analyst estimates vary greatly.
Recent Initiatives: Focus on advancing the CUE-100 series clinical trials and exploring new applications of the Immuno-STATETM platform.
Summary
Cue Biopharma is a clinical-stage biotech company with a novel Immuno-STATETM platform. It has the potential to make waves in the immuno-oncology space if its CUE-100 products prove successful. Its strengths include an IP portfolio and strong technology, however, it must be mindful of finances and continue to explore partnerships and additional funding avenues to execute trials. Overall, Cue Biopharma is an innovative company with significant long-term potential balanced by substantial risk due to its early stage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cue Biopharma Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cue Biopharma
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2018-01-02 | President & CEO Dr. Usman Azam M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.cuebiopharma.com |
Full time employees 41 | Website https://www.cuebiopharma.com | ||
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.